ANDA 90797, held by Actavis Totowa. Pantoprazole Sodium.
As of Nov 16, 2026, ANDA 90797 (Pantoprazole Sodium), held by Actavis Totowa, was first approved by FDA on Feb 7, 2011, with 10 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 7, 2011 | Original application | Approved | None posted |
| Pantoprazole SodiumEQ 20MG BASE · tablet, delayed release;oral | Pantoprazole Sodium | Discontinued |
| Pantoprazole SodiumEQ 40MG BASE · tablet, delayed release;oral | Pantoprazole Sodium | Discontinued |
| Mar 13, 2024 | Supplement 12Labeling · Standard review | Approved | None posted |
| Mar 13, 2024 | Supplement 13Labeling · Standard review | Approved | None posted |
| Mar 13, 2024 | Supplement 14Labeling · Standard review | Approved | None posted |
| Mar 13, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| Apr 9, 2015 | Supplement 11Labeling · Standard review | Approved | None posted |
| Dec 10, 2014 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 10, 2014 | Supplement 10Labeling · Standard review | Approved | None posted |
| May 30, 2013 | Supplement 6Labeling · Standard review | Approved | None posted |
| May 30, 2013 | Supplement 7Labeling · Standard review | Approved | None posted |
| Mar 23, 2012 | Supplement 4Labeling | Approved | None posted |
| Feb 7, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters